TPT1 was predicted as the candidate target of miR-216a-5p (Fig. 4A), which has been reported to contribute to tumor progression such as hepatocellular carcinoma, lung cancer and prostate cancer 17. This evidence concerns the gene TPT1 and prostate carcinoma.